Renal

Localized
- T1b or greater (has not spread beyond the kidney)
- No Prior Systemic Therapy
  - IRB# 20148 XL184-313: Phase 3 Randomized Study of Cabozantinib with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab
  - IRB# 19991 A017004: PD-Inhibitor (Nivolumab) and Ipilimumab Followed By Nivolumab vs VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)
  - IRB# 19661 EA8143: Phase 3 Randomized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized RCC Undergoing Nephrectomy (PROSPER)

Clear Cell
- Nephrectomy Candidate
  - IRB# 19283 Xynomic Pazopanib +/- Abexinostate in Patients with locally advanced or Metastatic RCC

Non-Clear Cell
- Metastatic/locally advanced
  - Prior Systemic Therapy
    - No prior VEGF. Up to 1 prior cytokine or immune checkpoint inhibitor
    - Track 2: Prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4
  - Progression on anti-PD-1/PD-L1 mAb monotherapy or in combo w/ other therapies
  - IRB# 11804 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) + Pembro

Papillary Renal Carcinoma
- IRB# 16085 S1500 – Cabozantinib, Crizotinib, Savolitinib and sunitinib

CROSS-DISEASE TRIALS

IRB# 19992 EAY 131 (MATCH)
IRB# 18084 S1609 (DART)

http://www.ohsu.edu/research/rda/so/knight.php

02DEC2019